AI주식인사이트AI Stock Insight
B

현대약품

004310KOSPI

57.8 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40
News Sentiment16.8 / 25
Momentum17.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 36.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai Pharm focuses on the production and sale of prescription and OTC pharmaceuticals, food, cosmetics, and medical devices, supplying products such as hypertension medication Tenolmin, hair loss treatment Minoxil, and dietary fiber beverage Mieyro Haiiba both domestically and internationally. The company has established a competitive edge in the functional cosmetics market through its brand Labcle, which emphasizes eco-friendly ingredients and sustainable packaging, aligning with global green consumption trends.

Number of Employees

399people

Average Salary

71.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
87.71Industry Average 15.000.0Point

5.8x industry avg (risky)

PBR
3.28Industry Average 1.200.0Point

2.7x industry avg (risky)

ROE
3.12Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
11.82Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲3.2% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲1051.5% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.2% (declining, 3yr)

Detailed News Sentiment

10 totalPositive 5Neutral 5Negative 0Average Sentiment Score 67

Detailed Momentum

52-week position5.0Point

52w mid range (45%)

Current 8,420Won52-week high 14,34052-week low 3,545
1-month return6.0Point

1m +36.91% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0